Residual Stroke Risk in Atrial Fibrillation

AF contributes to increased stroke risk via various mechanisms, including deranged blood constituents, vessel wall abnormalities and abnormal blood flow. This excess risk is frequently managed with anticoagulation therapy, aimed at preventing thromboembolic complications. Yet, a significant proporti...

Descripción completa

Detalles Bibliográficos
Autor principal: Ding, Wern Yew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2021
Materias:
Clinical Arrhythmias
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576486/
https://www.ncbi.nlm.nih.gov/pubmed/34777818
http://dx.doi.org/10.15420/aer.2021.34
_version_ 1784595886444118016
author Ding, Wern Yew
author_facet Ding, Wern Yew
author_sort Ding, Wern Yew
collection PubMed
description AF contributes to increased stroke risk via various mechanisms, including deranged blood constituents, vessel wall abnormalities and abnormal blood flow. This excess risk is frequently managed with anticoagulation therapy, aimed at preventing thromboembolic complications. Yet, a significant proportion of patients with AF remain at high residual stroke risk despite receiving appropriate dose-adjusted anticoagulation. This article explores the residual stroke risk in AF and potential therapeutic options for these patients.
format Online
Article
Text
id pubmed-8576486
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Radcliffe Cardiology
record_format MEDLINE/PubMed
spelling pubmed-85764862021-11-12 Residual Stroke Risk in Atrial Fibrillation Ding, Wern Yew Arrhythm Electrophysiol Rev Clinical Arrhythmias AF contributes to increased stroke risk via various mechanisms, including deranged blood constituents, vessel wall abnormalities and abnormal blood flow. This excess risk is frequently managed with anticoagulation therapy, aimed at preventing thromboembolic complications. Yet, a significant proportion of patients with AF remain at high residual stroke risk despite receiving appropriate dose-adjusted anticoagulation. This article explores the residual stroke risk in AF and potential therapeutic options for these patients. Radcliffe Cardiology 2021-10 /pmc/articles/PMC8576486/ /pubmed/34777818 http://dx.doi.org/10.15420/aer.2021.34 Text en Copyright © 2021, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
spellingShingle Clinical Arrhythmias
Ding, Wern Yew
Residual Stroke Risk in Atrial Fibrillation
title Residual Stroke Risk in Atrial Fibrillation
title_full Residual Stroke Risk in Atrial Fibrillation
title_fullStr Residual Stroke Risk in Atrial Fibrillation
title_full_unstemmed Residual Stroke Risk in Atrial Fibrillation
title_short Residual Stroke Risk in Atrial Fibrillation
title_sort residual stroke risk in atrial fibrillation
topic Clinical Arrhythmias
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576486/
https://www.ncbi.nlm.nih.gov/pubmed/34777818
http://dx.doi.org/10.15420/aer.2021.34
work_keys_str_mv AT dingwernyew residualstrokeriskinatrialfibrillation

Ejemplares similares